Table 3. Characteristics of patients included in the evaluation of comparative outcomes for generic or authorized generic (AG) versus brand initiators after 1:1 propensity score matching in each database.
| Characteristic | Optum | MarketScan | ||||||
|---|---|---|---|---|---|---|---|---|
| Generic versus brand-name | AG versus brand-name | Generic versus brand-name | AG versus brand-name | |||||
| Generic initiators | Brand-name initiators | AG initiators | Brand-name initiators | Generic initiators | Brand-name initiators | AG initiators | Brand-name initiators | |
| Alendronate | ||||||||
| Number of patients | 26,421 | 26,421 | 2,428 | 2,428 | 112,820 | 112,820 | 11,958 | 11,958 |
| Age: mean (SD) | 59 (10) | 59 (10) | 60 (10) | 60 (10) | 64.01 (12) | 64.25 (12) | 63.48 (12) | 63.22 (12) |
| Male sex: n (%) | 2,525 (9.6%) | 2,535 (9.6%) | 217 (8.9%) | 223 (9.2%) | 12,369 (11.0%) | 12,545 (11.1%) | 1,234 (10.3%) | 1,253 (10.5%) |
| Osteoporosis: n (%) | 10,342 (39.1%) | 10,229 (38.7%) | 972 (40.0%) | 951 (39.2%) | 30,753 (27.3%) | 30,929 (27.4%) | 3,465 (29.0%) | 3,417 (28.6%) |
| Amlodipine | ||||||||
| Number of patients | 69,478 | 69,478 | 25,259 | 25,259 | 32,740 | 32,740 | 32,740 | 32,740 |
| Age: mean (SD) | 54 (13) | 54 (13) | 56 (13) | 56 (12) | 60.60 (15) | 60.64 (15) | 60.37 (15) | 60.64 (15) |
| Male sex: n (%) | 36,359 (52.3%) | 36,178 (52.1%) | 13,732 (54.4%) | 13,754 (54.5%) | 14,510 (44.3%) | 14,896 (45.5%) | 14,816 (45.3%) | 14,896 (45.5%) |
| Hypertension: n (%) | 51,437 (74.0%) | 51,891 (74.7%) | 19,303 (76.4%) | 19,223 (76.1%) | 19,678 (60.1%) | 19,530 (59.7%) | 19,477 (59.5%) | 19,530 (59.7%) |
| Amlodipine-benazepril | ||||||||
| Number of patients | 14,704 | 14,704 | 5,992 | 5,992 | 53,495 | 53,495 | 23,158 | 23,158 |
| Age: mean (SD) | 52 (12) | 52 (11) | 54 (12) | 53 (11) | 54.65 (13) | 54.65 (13) | 54.88 (12) | 54.65 (13) |
| Male sex: n (%) | 8,670 (59.0%) | 8,758 (59.6%) | 3,408 (56.9%) | 3,491 (58.3%) | 29,835 (55.8%) | 30,014 (56.1%) | 12,988 (56.1%) | 13,250 (57.2%) |
| Hypertension: n (%) | 10,543 (71.7%) | 10,453 (71.1%) | 4,280 (71.4%) | 4,131 (68.9%) | 31,951 (59.7%) | 31,660 (59.2%) | 13,840 (59.8%) | 13,584 (58.7%) |
| Calcitonin salmon | ||||||||
| Number of patients | 944 | 944 | 636 | 636 | 6,306 | 6,306 | 3,422 | 3,422 |
| Age: mean (SD) | 62 (12) | 62 (12) | 59 (13) | 60 (13) | 68.37 (14) | 68.42 (14) | 66.23 (15) | 65.77 (15) |
| Male sex: n (%) | 142 (15.0%) | 145 (15.4%) | 102 (16.0%) | 96 (15.1%) | 848 (13.4%) | 847 (13.4%) | 518 (15.1%) | 537 (15.7%) |
| Osteoporosis: n (%) | 437 (46.3%) | 440 (46.6%) | 272 (42.8%) | 262 (41.2%) | 2,227 (35.3%) | 2,165 (34.3%) | 1,189 (34.7%) | 1,196 (35.0%) |
| Escitalopram | ||||||||
| Number of patients | 53,711 | 53,711 | 25,540 | 25,540 | 297,843 | 297,843 | 103,016 | 103,016 |
| Age: mean (SD) | 39 (15) | 39 (15) | 39 (15) | 39 (15) | 42.58 (17) | 42.46 (17) | 42.61 (18) | 42.20 (17) |
| Male sex: n (%) | 17,870 (33.3%) | 17,982 (33.5%) | 8,790 (34.4%) | 8,725 (34.2%) | 94,821 (31.8%) | 94,674 (31.8%) | 32,963 (32.0%) | 32,891 (31.9%) |
| Depression: n (%) | 5,349 (10.0%) | 5,160 (9.6%) | 2,593 (10.2%) | 2,556 (10.0%) | 31,146 (10.5%) | 30,921 (10.4%) | 10,401 (10.1%) | 9,875 (9.6%) |
| Anxiety: n (%) | 5,657 (10.5%) | 5,383 (10.0%) | 2,666 (10.4%) | 2,436 (9.5%) | 26,017 (8.7%) | 26,425 (8.9%) | 8,883 (8.6%) | 8,420 (8.2%) |
| Glipizide | ||||||||
| Number of patients | 997 | 997 | 825 | 825 | 2,388 | 2,388 | 2,246 | 2,246 |
| Age: mean (SD) | 58 (13) | 58 (13) | 58 (11) | 58 (12) | 60.98 (14) | 61.67 (13) | 61.66 (13) | 61.79 (13) |
| Male sex: n (%) | 539 (54.1%) | 506 (50.8%) | 452 (54.8%) | 440 (53.3%) | 1,223 (51.2%) | 1,203 (50.4%) | 1,124 (50.0%) | 1,134 (50.5%) |
| Diabetes mellitus: n (%) | 695 (69.7%) | 722 (72.4%) | 596 (72.2%) | 605 (73.3%) | 1,539 (64.4%) | 1,546 (64.7%) | 1,488 (66.3%) | 1,495 (66.6%) |
| Quinapril | ||||||||
| Number of patients | 4,480 | 4,480 | 3,684 | 3,684 | 8,049 | 8,049 | 9,262 | 9,262 |
| Age: mean (SD) | 53 (12) | 53 (13) | 54 (12) | 54 (12) | 56.58 (14) | 56.55 (14) | 58.48 (14) | 58.47 (14) |
| Male sex: n (%) | 2,579 (57.6%) | 2,599 (58.0%) | 2,121 (57.6%) | 2,138 (58.0%) | 4,163 (51.7%) | 4,189 (52.0%) | 5,006 (54.0%) | 5,039 (54.4%) |
| Hypertension: n (%) | 2,694 (60.1%) | 2,653 (59.2%) | 2,256 (61.2%) | 2,242 (60.9%) | 3,577 (44.4%) | 3,481 (43.2%) | 4,218 (45.5%) | 4,160 (44.9%) |
| Sertraline | ||||||||
| Number of patients | 54,493 | 54,493 | 55,674 | 55,674 | 132,986 | 132,986 | 132,056 | 132,056 |
| Age: mean (SD) | 40 (15) | 39 (15) | 39 (15) | 38 (15) | 43.82 (18) | 43.71 (18) | 42.45 (17) | 42.43 (18) |
| Male sex: n (%) | 17,110 (31.4%) | 16,884 (31.0%) | 17,472 (31.4%) | 17,303 (31.1%) | 41,625 (31.3%) | 41,141 (30.9%) | 41,584 (31.5%) | 41,392 (31.3%) |
| Depression: n (%) | 4,985 (9.1%) | 4,685 (8.6%) | 5,278 (9.5%) | 4,887 (8.8%) | 9,312 (7.0%) | 8,656 (6.5%) | 9,919 (7.5%) | 9,364 (7.1%) |
| Anxiety: n (%) | 4,025 (7.4%) | 3,833 (7.0%) | 4,323 (7.8%) | 3,896 (7.0%) | 6,101 (4.6%) | 5,761 (4.3%) | 6,660 (5.0%) | 6,160 (4.7%) |